Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | NY-ESO-1: a promising target for sarcoma treatment

Robin Jones, MD, The Royal Marsden Hospital, London, UK, comments on the potential of targeting NY-ESO-1 in sarcomas, noting its relevance in both synovial sarcoma and myxoid liposarcoma, and highlighting the promising results of the FDA-approved Fosbretabulin, which may pave the way for further developments in this area. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.